Analysis
China's pharmaceutical industry is undergoing a major transformation, with significant changes expected for traditional Chinese medicines. This regulatory push encourages pharmaceutical companies to enhance safety information and data, paving the way for a more robust and innovative sector.
Key Takeaways
- •A significant portion of existing Chinese patent medicines face potential delisting.
- •The regulatory change focuses on improving the transparency and completeness of safety data.
- •This is expected to drive innovation and improvements within the industry.
Reference / Citation
View Original"This means, of the approximately 57,000 effective approval documents for Chinese patent medicines currently in existence in China, more than 70% of the documents with problems in safety information labeling will face elimination."